# Eyenovia

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eyenovia

- Industry: Medical Devices & Equipment
- Headquarters: New York, US
- Website: www.eyenovia.com
- Latest round: Series A (Apr 15, 2015)
- Investors on record: 4

## About

Eyenovia, Inc., based in the US, specializes in innovative ophthalmic technologies to improve patient outcomes in eye care, notably through their advanced delivery system for eye medications.Founded in 2014 and headquartered in New York, US, Eyenovia, Inc. focuses on developing technologies for eye care. The company raised USD 27.3 mn in an IPO in January 2018, followed by USD 12.6 mn in August 2020. The CEO is Michael Rowe, who has extensive experience in the medical technology sector.Eyenovia, now rebranded as Hyperion DeFi, Inc., develops innovative ophthalmic technologies. Its flagship product, Optejet®, enhances medication delivery for conditions like glaucoma, ensuring accurate dosing and better patient adherence. This device is utilized by ophthalmologists and eye care professionals across North America and select international markets, streamlining therapeutic applications for improved treatment outcomes.In the most recent year, 2024, Eyenovia reported revenue of USD 57.34 mn and an EBITDA of USD -6.85 mn, generated primarily through direct sales to healthcare providers, hospitals, and clinics, with a focus on structured agreements and exclusive contracts.Eyenovia aims to launch new products, including enhancements to their Optejet® system, aimed for release in the coming year. The company is also targeting expansion into additional international markets, backed by recent funding of USD 50.00 mn raised in August 2020. This funding will support product development and market entry strategies, aligning with the firm’s goal of increasing its footprint in the ophthalmic sector.

## Funding rounds

- Series A, Apr 15, 2015 — Mario Family Partners, Eshelman Ventures, Private Medical Equity, LLC, Senju Pharmaceutical Co., Ltd

## Investors

- Mario Family Partners — Series A
- Eshelman Ventures (https://capitalatlas.ai/funds/eshelman-ventures) — Series A
- Private Medical Equity, LLC — Series A
- Senju Pharmaceutical Co., Ltd — Series A